In the gritty reality of warfare, where every second can be a matter of life and death, MediWound, an Israeli beacon of biopharmaceutical innovation, has thrown a lifeline to our boys in the field.

They’ve recently bagged a hefty $6.7 million on top of an initial $6.5 million, bringing the war chest to a whopping $14.4 million.

This isn’t just money; it’s a new dawn in treating burns that doesn’t involve a knife and peeling away layers of burnt flesh.

A Partnership Forged in Urgency

The US Department of Defense (DoD), in cahoots with the Medical Technology Enterprise Consortium (MTEC), has bet big on MediWound’s NexoBrid.